Articles in this Issue

• 

  RNA's comeback tour

  Wednesday, August 19, 2026
  RNA’s reputation may have been forged by a pandemic, but its future will likely be determined by something far less dramatic: the steady accumulation of clinical data, regulatory milestones and, ... read more
• 

  Global by default

  Wednesday, August 26, 2026
  For many CGT companies, the U.S. has long been the default starting point for new ventures. In recent years, that model appears to be weakening, as more companies look beyond the U.S. earlier in their... read more
• 

  RNA rocks on

  Tuesday, September 01, 2026
  As the next generation of RNA therapeutics takes the CGT stage, the technology is moving beyond its COVID-era breakout role. It could enable new approaches to in vivo CAR-T, address diseases beyond ... read more